Format

Send to

Choose Destination
Oncotarget. 2014 Feb 28;5(4):872-81.

miR-34: from bench to bedside.

Author information

1
Medical Research Council, Toxicology Unit, Leicester University, Leicester, UK.

Abstract

The mir-34 family was originally cloned and characterized in 2007 as a p53 target gene. Almost immediately it became clear that its major role is as a master regulator of tumor suppression. Indeed, when overexpressed, it directly and indirectly represses several oncogenes, resulting in an increase of cancer cell death (including cancer stem cells), and in an inhibition of metastasis. Moreover, its expression is deregulated in several human cancers. In 2013, a miR-34 mimic has become the first microRNA to reach phase 1 clinical trials. Here we review the miR-34 family and their role in tumor biology, and discuss the potential therapeutic applications of miR-34a mimic.

PMID:
24657911
PMCID:
PMC4011589
DOI:
10.18632/oncotarget.1825
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center